Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 234 Neoplasms 207 Carcinoma, Non-Small-Cell Lung 101 Colorectal Neoplasms 99 Prostatic Neoplasms 89 Lung Neoplasms 77 Multiple Myeloma 53 Melanoma 51 Pancreatic Neoplasms 50 Head and Neck Neoplasms 49 Neoplasm Metastasis 48 Leukemia, Myeloid, Acute 44 Carcinoma, Hepatocellular 43 Ovarian Neoplasms 39 Brain Neoplasms 39 Squamous Cell Carcinoma of Head and Neck 37 Recurrence 37 Glioblastoma 33 Uterine Cervical Neoplasms 32 Glioma 30 Sarcoma 29 Precursor Cell Lymphoblastic Leukemia-Lymphoma 29 Stomach Neoplasms 28 Lymphoma, Non-Hodgkin 28 Lymphoma 27 Colonic Neoplasms 27 Carcinoma, Renal Cell 26 Lymphoma, Follicular 25 Esophageal Neoplasms 24 Rectal Neoplasms 23

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Genomic Instability × 90 days × Clear all

NCT02314481 2026-05-04

DARWINII

University College, London

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡